CD274 and non-small cell lung carcinoma: This trial randomized 358 patients to 3 cycles of neoadjuvant platinum doublet versus the combination of nivolumab with platinum doublet in Stage IB-IIIA (64% Stage IIIA) NSCLC, in which half were PD-L1 ≥1%.